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Abstract
Background: Linear nevus sebaceous syndrome (LNSS) is a multisystem disorder that includes nevus sebaceous
and central nervous system, ocular and skeletal anomalies. We report the first case of a KRAS G12D mosaic mutation
in a patient diagnosed with LNSS.
Case presentation: A 3-month-old female with a clinical diagnosis of LNSS presented with intermittent epilepsy.
Her mother carefully collected a skin lesion sample from scratched-off scurf obtained from the patient’s nails. DNA
was extracted, and long-range PCR was performed to amplify the KRAS gene, which was then analyzed by
next-generation sequencing. The results revealed the presence of a low-level heterozygous mutation in the
KRAS gene (c.35C>T; p.G12D, 5 %).
Conclusions: These findings suggest that the KRAS somatic mosaic mutation in this patient may have caused
her skin and eye lesions and epilepsy. With this correct diagnosis, the infant can be effectively treated.
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Background
Linear nevus sebaceous syndrome (LNSS) is a rare, con-
genital neurocutaneous syndrome characterized by mid-
line facial skin lesions (linear nevus sebaceous), seizures
and mental retardation [1]. Several syndromes, including
Schimmelpenning-Feuerstein-Mims (SFM) syndrome,
epidermal nevus syndrome, organoid nevus syndrome
and Jadassohn nevus phakomatosis (OMIM 163200),
have been classified as a group of disorders characterized
by various types of epidermal nevi [2–4]. These syn-
dromes occur sporadically with no sexual predilection,
and no associated chromosomal abnormalities have been
found [3, 5]. Nevus sebaceous (NS), a hallmark of LNSS,
is a hamartoma that can be found on the epidermis, hair
follicles and sebaceous and apocrine glands [1]. NS is es-
timated to occur in 0.3 % of newborns. It is character-
ized by yellowish-orange to pink lesions that are often
oval or linear, sharply demarcated and slightly raised and
present as waxy or pebbly surfaces on the skin of the
head, face and neck. These lesions vary in size from a
few millimeters to several centimeters in length. The
typical life histories and histopathological findings of pa-
tients with sebaceous nevus are age dependent. Approxi-
mately 7 % of NS cases may have additional neurological,
ocular and skeletal defects. Epilepsy occurs in up to 25 %
of patients and is especially common in LNSS, with a re-
ported incidence of as high as 75 % [6].
These disorders are the result of a genetic mosaicism
involving a lethal autosomal dominant gene. A case re-
port of discordant monozygotic (MZ) twins with severe
SFM has hypothesized that this syndrome may be due to
a postzygotic mutation [7, 8]. However, familial aggrega-
tion may sometimes be observed. These disorders may
be explained by para-dominant inheritance [9]. Recently,
somatic mosaicism has been demonstrated with activat-
ing RASopathy mutations in HRAS or KRAS in NS
lesional keratinocytes. Mutations can lead to constitutive
activation of the RAF-MEK-ERK signaling pathways and
result in increased cellular proliferation. The most com-
mon mutation is c.37G>C (p.Gly13Arg) in HRAS, which
is present in >90 % of NS cases [6]. Here, we report a
Chinese infant LNSS patient with intermittent epilepsy
and ocular pterygium who has a KRAS G12D mosaic
mutation, which was detected by performing next-
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A female infant was born at 37 + 1 weeks of gestation by
cesarean section due to central placenta previa. The
young mother experienced polyhydramnios in her last
gestation. The birth weight of the baby was 2700 g. Im-
mediately after birth, the infant was found to have mul-
tiple skin lesions on her head and eyes (Fig. 1), including
two linear and one round skin lesion on the right side of
her head. The lesions were well demarcated, raised, vel-
vety plaques containing no hair. An invasive skin lesion
was observed on her right eye that caused the eyelid to
remain open. She had an ocular pterygium that pushed
down on her right pupil. Peripheral blood karyotype
analysis revealed a normal female karyotype without any
other chromosomal abnormalities. She began to have
weak intermittent lip cyanosis at the age of 3 months
that lasted up to 3 min and occurred 2–3 times per day.
She was a patient at our hospital, and her long-term
video EEG showed abnormal waves. Brain CT scan re-
vealed a partially widened gap between the brain and
skull, particularly on the right side and the top left side
of the temple. No significant changes in the lungs or
heart were detected by X-ray or B-ultrasonic examin-
ation, respectively. She was diagnosed with new-onset
seizures. She is able to grab, use baby talk and listen, but
her right eye cannot track her mother’s hand move-
ments. An intelligence test has not been performed.
Seizures have been controlled by administration of
oxcarbazepine; with this medication, the patient has had
fewer seizures.
Methods
Biopsy of the skin lesion was declined because of sei-
zures. A skin lesion sample from a scratched-off scurf
was carefully collected from the patient’s nails and saved
in RNAlater® Stabilization Solution (Thermo Fisher Sci-
entific, USA). Peripheral blood samples were also col-
lected from the patient and her parents. Genomic DNA
was extracted from the skin (QIAamp DNA Micro Kit,
Germany) and blood samples (QIAamp DNA Blood
Fig. 1 Linear nevus sebaceous involving the skin of the scalp and eyes. There are two linear and one round skin lesion with no hair, present as
well demarcated, raised, velvety plaques. The invasive skin lesion near her right eye causes her right eyelid to remain open. She has an ocular
pterygium that is pushing down on her right pupil
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Mini Kit, Germany). This study was approved by the
ethics committee of Children’s Hospital of Fudan Uni-
versity (2014–107) and was performed according to the
guidelines of the Declaration of Helsinki.
Targeted next-generation sequencing was performed
using an Ion Torrent Personal Genome Machine™ (Life
Technology, USA). Both amplicon-based and Ampliseq-
based library-building methods were used in this study.
Long-range PCR for analyses of the HRAS and KRAS
genes was performed using the patient’s tissue DNA for
amplicon-based library building. A PCR product library
was prepared according to the instructions provided by
the manufacturers of the kits for fragmentation (Ion
Shear, Life Technologies, USA) and adaptor and barcode
ligation (Ion Xpress Barcode Adapters Kit, Life Tech-
nologies, USA). Then, DNA extracted from the patient’s
and parents’ blood samples was analyzed with a Noonan
Syndrome Ampliseq panel. This panel includes the
NRAS, RIT1, PTPN11, KARS, MAP2K1, SOS1, RAF1 and
BRAF genes, with coverage of all exons and 10 bp re-
gions from intron/splice sites. The Ampliseq panel
library was derived from multiple PCR reactions con-
ducted using Ion AmpliSeq™ HiFi Mix and Ion Ampli-
Seq™ Primer Pool, in addition to digestion of primer
sequences (Ion AmpliSeq™ Library Kits 2.0), and adaptor
and barcode ligation (Ion Xpress Barcode Adapters Kit,
Life Technologies, USA).
The amplicon- and Ampliseq-based libraries were
quantitated using real-time PCR with the Ion TaqMan
Assay (Ion Library Quantification Kit, Life Technologies,
USA). Construction and enrichment of the emulsion
PCR libraries were performed using an Ion OneTouch
instrument to clonally amplify the pooled barcoded li-
braries Ion Sphere™ particles. Sequencing was performed
on an Ion 316 sequencing chip according to the manu-
facturer’s protocol. Torrent Suite™ software was used to
compare the base calls. Then, licensed NextGENe soft-
ware (Softgenetics, USA) was used to complete data ana-
lysis. Somatic variants in the skin and blood samples
were identified after filtering out germline changes. The
allele frequency of a variant was calculated by dividing
the number of variant reads by the total number of reads
at the same nucleotide position.
Results
The results showed a mosaic missense mutation in the
KRAS (NM004985.4) gene in exon 1 (GGT-GAT,
c.35C>T, p.12Gly>Asp), resulting in a p.G12D amino
acid substitution (Fig. 2). The allele frequency of the al-
tered nucleotide in the skin lesion was 5 % (sequencing
Fig. 2 A low-level heterozygous mutation in the KRAS gene (c.35C>T; p.G12D, 5 %) was detected in a skin lesion sample collected from a
scratched-off scurf
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depth: 160/3200) in the amplicon-based library. This re-
sult was confirmed with the Noonan Syndrome Ampli-
seq panel (sequencing depth: 21/395). Deep sequencing
of DNA extracted from the blood samples from the pa-
tient and both parents did not reveal any KRAS muta-
tions. No other mutations were detected in the BRAF
and HRAS genes. Sanger-based sequencing was not per-
formed because of the low level of the mosaic mutation.
Discussion
NS presents at birth, is usually asymptomatic and has a
tendency to become more prominent in sebaceous and
apocrine components during puberty. Subsequently, sec-
ondary tumors, such as syringocystadenoma papilli-
ferum, syringoma, nodular hidradenoma, sebaceous
thelioma, and keratoacanthoma, may occur in approxi-
mately 25 % of NS cases, though most of them are be-
nign. Because of its cosmetic impact and low but
documented malignant potential, prophylactic excision
of nevus sebaceous at or before the onset of puberty has
been recommended in some studies [4, 10, 11]. However,
the recent identification of key epidermal signaling ab-
normalities that underlie the increased cell proliferation
indicates that the development of medical treatments for
NS that target the aberrant signaling pathways may be
feasible [6].
The KRAS gene is located on chr12p12.1 and consists
of six exons. Germline mutations in KRAS have been
identified in patients with cardiofaciocutaneous (CFC)
syndrome, Noonan syndrome [12, 13] and Costello syn-
drome [14]. Somatic KRAS mutations frequently occur
in lung, colorectal and pancreatic cancers [15, 16]. The
somatic KRAS c.35G>A mutation is the most frequent
KRAS mutation in human cancers according to the
COSMIC database. However, widespread expression of
KRAS c.35G>A is not tolerated during mouse embryonic
development [17]. Similarly, this mutation has not been
observed in human germline cells. Mutations in codons
12, 13 and 61, which are frequent in somatic cancers,
have not been identified among germline mutations.
Notably, functional analysis has shown that these germline
mutations are less activating than the KRAS c.35G>A
G12D mutation [18, 19].
The first KRAS G12D mutation was reported in an in-
fant with epidermal nevus, polycystic kidneys and
rhabdomyosarcoma [20]. This mosaic KRAS G12D mu-
tation was detected in both the epidermal component of
the EN and in the rhabdomyosarcoma, but not in the
unaffected tissues or normal skin or blood. This obser-
vation strongly suggests a somatic mosaicism. Since the
first case, Levinsohn and other authors have identified
four additional nevus sebaceous patients with a somatic
p.Gly12Asp KRAS mutation [21, 22]. These four patients
only have nevus sebaceous, with no other characteristics
described. Regarding the KRAS G12D mutation we re-
port here, the patient was clinically diagnosed with LNSS
and displayed linear nevus sebaceous, eye lesions and
epilepsy, in contrast with the previously reported NS
cases. Our patient had nevus sebaceous with a linear
configuration that involved the right side of the face, the
scalp and the ocular region, and she also had seizures.
LNSS is difficult to accurately diagnose and has the
potential for multisystem organ involvement. Many phy-
sicians are unaware of this syndrome, which may delay
diagnosis and treatment. In this report, we present an
LNSS case and describe the presentation and genetic
diagnosis, in addition to incorporating a review of the
current literature in this field. Mental retardation affects
up to 60 % of LNSS patients and is evident more fre-
quently in patients with hemimegalencephaly [22]. Known
cortical abnormalities include focal cortical dysplasia,
partial hemimegalencephaly and holohemispheric hemi-
megalencephaly. A few reports have addressed the util-
ity of cortical resection for epilepsy treatment and have
demonstrated significant improvements in seizure fre-
quencies [23, 24].
Conclusions
In this study, we present the first case of a female infant
from China with LNSS and eye lesions. This patent also
had a somatic mosaic KRAS mutation (c.35G>A;
p.Gly12Asp) that was identified in a cutaneous lesion.
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